[{"id":"15ebc24f-836d-4955-b1c1-9b9491f8cda7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895735","created_at":"2021-05-20T11:54:07.989Z","updated_at":"2024-07-02T16:34:26.348Z","phase":"Phase 2","brief_title":"Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer","source_id_and_acronym":"NCT04895735","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • MTAP • TYMS","pipe":" | ","alterations":" PD-L1 expression • TYMS expression","tags":["PD-L1 • MTAP • TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 06/03/2025","primary_completion_date":" 06/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2024-06-13"},{"id":"d21eaf49-ee7f-4da5-977a-cfbd0e3676b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03741829","created_at":"2021-01-18T18:19:42.728Z","updated_at":"2024-07-02T16:36:50.428Z","phase":"","brief_title":"TS Overexpression in SCLC: Mechanism and Therapeutic Targeting","source_id_and_acronym":"NCT03741829","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" TYMS","pipe":" | ","alterations":" TYMS expression","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TYMS expression"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/14/2017","start_date":" 06/14/2017","primary_txt":" Primary completion: 01/03/2020","primary_completion_date":" 01/03/2020","study_txt":" Completion: 01/03/2020","study_completion_date":" 01/03/2020","last_update_posted":"2020-02-05"},{"id":"ae9c765d-a27e-451d-9978-da5127fe63a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00449137","created_at":"2021-01-18T01:35:21.197Z","updated_at":"2024-07-02T16:37:27.058Z","phase":"Phase 1","brief_title":"Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment","source_id_and_acronym":"NCT00449137","lead_sponsor":"University of Miami","biomarkers":" TYMS","pipe":" | ","alterations":" TYMS expression","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • leucovorin calcium • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2005","start_date":" 06/01/2005","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2016-12-15"},{"id":"fc18a3b4-d245-4d27-ba5a-baa9f7f17ef0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01194453","created_at":"2021-01-18T04:46:49.793Z","updated_at":"2024-07-02T16:37:31.280Z","phase":"Phase 2","brief_title":"Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01194453","lead_sponsor":"Sun Yat-sen University","biomarkers":" TYMS • RRM1","pipe":" | ","alterations":" TYMS expression","tags":["TYMS • RRM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • pemetrexed • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 288","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 09/01/2010","primary_completion_date":" 09/01/2010","study_txt":" Completion: 08/01/2012","study_completion_date":" 08/01/2012","last_update_posted":"2016-06-16"}]